Received 1 June 2010/Returned for modification 15 November 2010/Accepted 18 December 2010
|
|
- Edith Blankenship
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2011, p Vol. 55, No /11/$12.00 doi: /aac Copyright 2011, American Society for Microbiology. All Rights Reserved. Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis Paschalis Vergidis, 1 Mark S. Rouse, 2 Gorane Euba, 1 Melissa J. Karau, 2 Suzannah M. Schmidt, 2 Jayawant N. Mandrekar, 3 James M. Steckelberg, 1 and Robin Patel 1,2 * Division of Infectious Diseases, Department of Internal Medicine, 1 Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, 2 and Division of Biomedical Statistics and Informatics, 3 Mayo Clinic, Rochester, Minnesota Received 1 June 2010/Returned for modification 15 November 2010/Accepted 18 December 2010 Rifampin monotherapy was compared to the combination of linezolid or vancomycin with rifampin in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) chronic foreign body osteomyelitis. MRSA was inoculated into the proximal tibia, and a titanium wire was implanted. Four weeks after infection, rats were treated intraperitoneally for 21 days with rifampin alone (n 16), linezolid plus rifampin (n 14), or vancomycin plus rifampin (n 13). Thirteen animals received no treatment. At completion of treatment, qualitative cultures of the wire and quantitative cultures of the bone (reported as median values) were performed. Quantitative cultures from the control, rifampin monotherapy, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups revealed 4.54, 0.71, 0.10, and 0.50 log 10 CFU/gram of bone, respectively. The bacterial load was significantly reduced in all treatment groups compared to that in the control group. Rifampin resistance was detected in isolates from 10, 2, and 1 animal in the rifampin, linezolid-plus-rifampin, and vancomycin-plus-rifampin groups, respectively. Cultures of the removed wire revealed bacterial growth in 1 and 2 animals in the rifampin and linezolid-plus-rifampin groups, respectively, with no growth in the vancomycin-plus-rifampin group and growth from all wires in the untreated group. In conclusion, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is effective in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body. The pathogenesis of chronic orthopedic prosthetic infections is related to the presence of organisms growing in biofilm. Within biofilms, there is an altered microenvironment which may compromise antimicrobial action independent of traditional mechanisms of antimicrobial resistance. Proposed mechanisms include decreased antimicrobial activity against stationary-growth-phase bacteria, modification of antimicrobial agents by inactivating enzymes, decreased penetration, and the presence of persister cells (7). Management of orthopedic device infections typically involves antimicrobial treatment in combination with a surgical approach. In cases of hardware retention, Staphylococcus aureus infections are often treated with the combination of a nonrifamycin antistaphylococcal agent plus rifampin (8, 29). Indeed, rifampin exhibits bactericidal activity against organisms growing in biofilm, but when administered alone, it is associated with rapid emergence of resistance. S. aureus isolates growing in biofilm demonstrate poor antimicrobial susceptibility compared to the planktonic forms of the same isolates (23, 26). Compounding the issue, methicillin-resistant S. aureus (MRSA) strains with reduced susceptibility to vancomycin have been identified (1). Although vancomycin is considered the drug of choice for invasive infections due to MRSA, alternative agents, such as linezolid, can be used in cases of adverse events or nonsusceptibility to vancomycin. In addition, linezolid has excellent oral bioavailability and thus may be conveniently administered. However, clinical data supporting the use of linezolid for orthopedic prosthetic infections are limited to small nonrandomized studies (3, 19, 21, 22, 28). In a preliminary experimental rat study of methicillin-susceptible S. aureus (MSSA) foreign body infection, we demonstrated that neither vancomycin nor linezolid alone resulted in a significant decrease in the numbers of bacteria in the bone surrounding the implant or on the implant itself (11). No resistance to either antimicrobial was noted at the end of treatment. Herein, we used the same rat model of experimental foreign body infection but evaluated rifampin monotherapy and rifampin in combination with either linezolid or vancomycin against MRSA. (This work was presented in part at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 12 to 15 September 2010.) * Corresponding author. Mailing address: Division of Clinical Microbiology, Mayo Clinic, 200 First St. SW, Rochester, MN Phone: (507) Fax: (507) Present address: Department of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona 08907, Spain. Published ahead of print on 28 December MATERIALS AND METHODS Microorganism. MRSA IDRL 6169, originally recovered from a patient with a prosthetic joint infection, was studied. Antimicrobial agents. Vancomycin was obtained from Hospira Inc., Lake Forest, IL. Linezolid was obtained from Pfizer Inc., New York, NY. Rifampin was obtained from Akorn Strides, Lake Forest, IL. The MIC of each antimicrobial agent was determined by broth microdilution using an inoculum of CFU/ml according to Clinical and Laboratory Standards Institute (CLSI) guide- 1182
2 VOL. 55, 2011 COMBINATION TREATMENT IN ANIMAL MODEL OF OSTEOMYELITIS 1183 TABLE 1. Pharmacokinetic studies of rifampin, linezolid, and vancomycin a Antimicrobial (reference) Dose (mg/kg) Serum concn of drug SD ( g/ml) at: 0.5 h 1 h 2 h 4 h 6 h 8 h 12 h AUC 0-24 ( g h/ml) Rifampin Linezolid (11) Vancomycin (24) All a The antimicrobials were administered intraperitoneally every 12 h. Drug concentrations were measured at steady state (after 3 doses) from at least 4 animals at each time point for each antimicrobial agent. lines (4). Similarly, the minimum bactericidal concentration (MBC) was determined according to CLSI guidelines (5). Pharmacokinetic studies. The pharmacokinetic profile in rats of rifampin, linezolid, and vancomycin administered intraperitoneally was determined by measuring serum concentrations at 0.5, 1, 2, 4, 6, 8, and 12 h after administration (6). The antimicrobials were administered to 15 healthy male Wistar rats for each antimicrobial at the doses listed in Table 1. Serum drug concentrations were measured at steady state (after the third dose). Blood was collected by cardiac puncture or tail vein bleed at each time point, and serum was separated by centrifugation. Serum was placed on paper disks and allowed to diffuse into the bioassay plates (Mueller-Hinton agar with Bacillus subtilis as the indicator organism) for 30 min and then incubated at 30 C overnight. Zone sizes were measured using calipers, and concentrations were calculated by linear regression from a five-point standard curve. Rat serum was used as a diluent for control disks. Pharmacokinetic parameters were calculated using the PK Solutions 2.0 software program (Summit Research Services, Montrose, CO). Experimental rat model. The experimental model described was developed and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Mayo Clinic. Experimental chronic foreign body osteomyelitis was established in male Wistar rats using a modification of Zak s model of experimental osteomyelitis (18). In the modified model, we did not use sodium morrhuate, a sclerosing agent which induces bone damage, and we implanted a titanium wire which acts as a foreign body (Fig. 1). The left legs of the rats were shaved with an electric clipper, and the skin was disinfected with povidone-iodine, USP, 10% topical solution (prep solution; Novaplus, Novation, Inc., Irving, TX). Surgical anesthesia was induced with ketamine (60 mg/kg of body weight) (Ketasat, Fort Dodge, IA), xylazine (6 mg/kg) (Vettek; Phoenix Scientific Inc., St. Joseph, MO), and acepromazine (1 mg/kg) (Boehringer Ingelheim, St. Joseph, MO) administered intramuscularly. The proximal third of the left tibia was surgically exposed, and a 1.5-mm hole was drilled into the medullary cavity. Fifty microliter of 10 6 CFU suspension of the MRSA isolate was injected into the bone. Subsequently, a 10-mm by 1-mm titanium wire (Zimmer, Warsaw, IN) was implanted into the bone. The hole was covered with dental gypsum. The skin was closed with sutures, and the wound was sprayed with antiseptic. Four weeks after establishing infection, treatment was initiated. Sixty-one animals (weighing 215 to 475 g) were arbitrarily assigned to one of four study arms: no treatment (n 13), rifampin alone (n 16), linezolid plus rifampin (n 16), or vancomycin plus rifampin (n 16). Rifampin was administered at 25 mg/kg intraperitoneally twice daily, linezolid at 35 mg/kg intraperitoneally twice daily, and vancomycin at 50 mg/kg intraperitoneally twice daily. Treatment was administered for 21 days. Animals not surviving 21 days of antimicrobial treatment were removed from the experiment and not further studied. There were two deaths in the linezolid-plus-rifampin group and three deaths in the vancomycin-plus-rifampin group. There were no deaths in the other groups. Twelve hours after completion of antimicrobial therapy, the rats were sacrificed with 100 mg/kg of pentobarbital and the left tibia was aseptically removed. The tibia was frozen to 70 C. Bone within 5 mm of the implanted titanium wire from each animal was weighed and pulverized for quantitative bacterial culture. The pulverized bone was suspended in 2 ml of Trypticase soy broth (TSB), vortexed for 30 s, sonicated at 40 khz for 5 min, serially diluted, and plated on sheep blood agar plates. Quantitative culture results for bone were obtained after 48 h of incubation and expressed as log 10 CFU per gram of tissue. For qualitative cultures, 8 ml of sterile TSB was added to the remaining 2 ml broth containing pulverized bone and incubated for 48 h. For broth with evidence of growth, subcultures were obtained to confirm the presence of MRSA. The wire FIG. 1. Illustration of the Wistar rat model of chronic foreign body osteomyelitis. (Copyright, Mayo Foundation for Medical Education and Research; reproduced with permission.)
3 1184 VERGIDIS ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 2. Results of quantitative bone cultures. Median value, interquartile range, and individual results are shown for each study group. The differences between the control and each treatment group were statistically significant (P ). Cultures that demonstrated resistance to rifampin after treatment are shown in red. was aseptically removed, placed in 2 ml of TSB, vortexed, sonicated, and qualitatively cultured as described above. Emergence of resistance studies. For MRSA recovered from bone after treatment, the MIC of linezolid, rifampin, or vancomycin was determined for three colonies for each culture. Statistical methods. Descriptive statistics for MRSA log 10 CFU per gram of bone were summarized as medians and interquartile ranges. For statistical purposes, we considered an absence of any growth to be 0.1 log 10 CFU/gram of bone and growth in qualitative broth culture (but not in quantitative cultures) to be 0.5 log 10 CFU/gram of bone. Differences in median log 10 CFU of MRSA per gram of bone among the four groups were compared using the Kruskal-Wallis test. Further, pairwise comparisons of median log 10 numbers of CFU of MRSA per gram of bone between the four groups (i.e., control and three treatments) were made using the Wilcoxon rank sum test. Based on Bonferroni s correction for adjustment due to multiple comparisons, P values less than were considered statistically significant to account for the six pairwise comparisons. For comparison of emergence of rifampin resistance among the treatment groups, we used Fisher s exact test. P values less than were considered statistically significant in order to adjust for the multiple comparisons based on Bonferroni s correction. All tests were two sided. Analysis was performed using SAS software (version 9; SAS Institute, Inc., Cary, NC). RESULTS The MICs of the MRSA isolate for each antimicrobial were as follows: oxacillin, 128 g/ml; vancomycin, 1 g/ml; rifampin, g/ml; and linezolid, 0.25 g/ml. The MBCs of the isolate were as follows: vancomycin, 1 g/ml; rifampin, g/ml; and linezolid, 128 g/ml. The pharmacokinetics of rifampin, linezolid, and vancomycin are shown in Table 1. The data for linezolid (11) and vancomycin (24) were obtained from previous studies. The area under the concentration-time curve from 0 to 24 h (AUC 0 24 ) was 332 g h/ml for rifampin, 278 g h/ml for linezolid, and 264 g h/ml for vancomycin. Experimental rat model. Results of quantitative cultures of bone after treatment are summarized in Fig. 2. MRSA was cultured from all harvested bones in the control group at a median of 4.54 (range, 3.46 to 5.80) log 10 CFU/gram of bone. After treatment, the median count of MRSA was 0.71 (range, 0.10 to 4.51) log 10 CFU/gram of bone in the rifampin group. The median counts were 0.10 (range, 0.10 to 3.11) log 10 CFU/ gram of bone in the linezolid-plus-rifampin group and 0.50 (range, 0.10 to 2.39) log 10 CFU/gram of bone in the vancomycin-plus-rifampin group. Differences in colony counts compared to the control group were significant in all treatment groups (P ). There was no significant difference between the rifampin group and the linezolid-plus-rifampin group (P 0.11), between the rifampin group and the vancomycin-plus-rifampin group (P 0.29), or between the linezolid-plus-rifampin group and the vancomycin-plus-rifampin group (P 0.62). Cultures of the titanium wires were also obtained. MRSA was cultured from titanium wires in all control animals. There was no growth in 15/16 animals (94%) in the rifampin group, in 12/14 animals (86%) in the linezolid-plus-rifampin group, and in 13/13 animals in the vancomycin-plus-rifampin group. Emergence of resistance (rifampin MIC after treatment, 1 g/ml) was detected in isolates from 10 animals (63%) in the rifampin group, 2 animals (14%) in the linezolid-plus-rifampin group, and 1 animal (8%) in the vancomycin-plusrifampin group. The differences between the monotherapy and combination treatment groups were statistically significant (P between the rifampin monotherapy and linezolid-plus-rifampin groups, and P between the rifampin monotherapy and vancomycin-plus-rifampin groups). The findings remained significant in spite of adjusting for multiple comparisons. There was no emergence of
4 VOL. 55, 2011 COMBINATION TREATMENT IN ANIMAL MODEL OF OSTEOMYELITIS 1185 resistance to linezolid or vancomycin in the respective treatment groups. DISCUSSION In the present study, we demonstrated that combination treatment with linezolid plus rifampin or vancomycin plus rifampin is more effective than no treatment in an animal model of MRSA foreign body osteomyelitis in the context of retention of the infected foreign body. We studied an MRSA isolate recovered from a patient with prosthetic joint infection. We treated the animals for 21 days; previous studies performed in our laboratory had demonstrated that this is the optimal duration of therapy of experimental osteomyelitis not associated with a foreign body (20). Other investigators have used the same duration of parenteral antimicrobial treatment in a rat model of foreign body-associated osteomyelitis involving the tibia (12, 15). Five deaths occurred, all in animals receiving combination therapy. Combination treatment involved two intraperitoneal injections, whereas rifampin was administered as a single injection each time. In addition, the volume of the injected rifampin was lower than that of the other drugs. Of note, in previous experiments with monotherapy we did not observe any rat losses. Hence we suspect that the deaths were related to puncture of a major vessel or a visceral organ and were not due to an effect of the infection or specific drug toxicity. Indeed, one of the deaths occurred immediately after the injection. The animal losses did not affect the statistical power of our study to detect differences among the groups. In a previous study, we demonstrated that linezolid or vancomycin alone did not eradicate infection in a rat model of MSSA foreign body osteomyelitis (11). More specifically, the median counts were 3.87 log 10 CFU/gram of bone for vancomycin alone, 4.98 for linezolid, and 5.45 for the untreated control group. MSSA was recovered from wire cultures in 12/15 animals (80%) in the vancomycin group, 14/15 animals (93%) in the linezolid group, and 10/12 animals (83%) in the control group. Differences among the groups for either the bone or the wire cultures were not statistically significant after adjusting for multiple comparisons. In the present study, we have demonstrated in vivo activity of rifampin administered alone or in combination with linezolid or vancomycin against MRSA. Rifampin monotherapy was associated with a significantly higher emergence of resistance than combination treatment. Nonetheless, rifampin resistance was detected even with combination treatment. Emergence of resistance should be considered in cases of clinical treatment failure, even with the use of rifampin combination therapy. Even in the context of resistant isolates, low colony counts were measured by quantitative cultures. There was no emergence of resistance for either linezolid or vancomycin. Notably, though, both antimicrobials were given in combination with rifampin and not as monotherapy. Still, in our prior study (11) where these agents were given alone, we did not note emergence of resistance. To our knowledge, this is the first article to report the outcome of combination treatment with linezolid plus rifampin in an animal model of foreign body infection with bone involvement. Our findings are in accordance with results reported by other investigators in different models employing guinea pigs or rats (2, 16). In these models, multiperforated polytetrafluoroethylene (Teflon) tissue cages were subcutaneously implanted in the flanks of the study animals. There was no involvement of bone with infection. The efficacy of combination treatment with rifampin and other antistaphylococcal agents, including teicoplanin (27) and daptomycin (13), has been shown in other animal experiments where, again, tissue cages were employed. The activity of combination treatment with rifampin plus linezolid was also shown in a rat model of vascular graft infection (25). We harvested the bone for culture 12 h after treatment cessation. Other investigators have harvested bone at later time points (9, 14, 17). Antibiotic carryover may explain culture negativity, particularly for the wires, a potential limitation of our study. Notably, in a tissue cage-associated MRSA infection model, Baldoni et al. showed 50 to 60% cure rates against adherent bacteria 5 days after cessation of combination treatment with linezolid and rifampin (2). The pharmacokinetic studies showed that the linezolid, vancomycin, and rifampin levels obtained a half-hour after injection were above the peak levels that are considered therapeutic in humans. The half-life of linezolid and vancomycin was shorter than that in humans, and vancomycin trough levels were undetectable. Nevertheless, culture results suggest activity of the study drugs at the concentrations administered. Rifampin levels were detectable at trough. Regarding drug-drug interactions, in healthy male volunteers, coadministration of linezolid with rifampin resulted in a decrease in the levels of linezolid (10). The clinical relevance of this observation is unknown. The medication is not an inducer of the cytochrome P-450 enzymes, and the mechanism of interaction has not been elucidated. There is no known interaction between vancomycin and rifampin. In conclusion, we demonstrated that the combination of linezolid plus rifampin or vancomycin plus rifampin is efficacious in a rat model of MRSA chronic osteomyelitis. Combination treatment was associated with lower rates of emergence of rifampin resistance. Resistance to either linezolid or vancomycin was not demonstrated. The results provide data that may be useful to clinicians treating orthopedic prosthetic or other biofilm-associated infections. ACKNOWLEDGMENT We thank Pfizer, Inc., for supporting the studies performed herein. REFERENCES 1. Appelbaum, P. C Reduced glycopeptide susceptibility in methicillinresistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30: Baldoni, D., M. Haschke, Z. Rajacic, W. Zimmerli, and A. Trampuz Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53: Bassetti, M., et al Linezolid in the treatment of Gram-positive prosthetic joint infections. J. Antimicrob. Chemother. 55: CLSI Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M07-A8, vol. 29, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA. 5. CLSI/NCCLS Methods for determining bactericidal activity of antimicrobial agents; Approved guideline. CLSI document M26-A, vol. 19, no. 18. CLSI/NCCLS, Wayne, PA. 6. Cozens, R Formulation of compounds and determination of pharmacokinetic parameters, p In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, San Diego, CA.
5 1186 VERGIDIS ET AL. ANTIMICROB. AGENTS CHEMOTHER. 7. del Pozo, J. L., and R. Patel The challenge of treating biofilm-associated bacterial infections. Clin. Pharmacol. Ther. 82: Del Pozo, J. L., and R. Patel Clinical practice. Infection associated with prosthetic joints. N. Engl. J. Med. 361: Dworkin, R., et al Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillinresistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34: Egle, H., R. Trittler, K. Kummerer, and S. W. Lemmen Linezolid and rifampin: drug interaction contrary to expectations? Clin. Pharmacol. Ther. 77: Euba, G., et al Linezolid treatment of Staphylococcus aureus experimental foreign body osteomyelitis. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B Gracia, E., et al Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. J. Surg. Res. 79: John, A. K., et al Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53: Littlewood-Evans, A. J., M. Hattenberger, O. Zak, and T. O Reilly Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. J. Antimicrob. Chemother. 39: Monzon, M., et al A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J. Orthop. Res. 19: Murillo, O., et al Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J. Infect. 57: O Reilly, T., et al Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob. Agents Chemother. 36: O Reilly, T., and J. Mader Rat model of bacterial osteomyelitis of the tibia, p In O. Zak and M. Sande (ed.), Handbook of animal models of infection. Academic Press, San Diego, CA. 19. Papadopoulos, A., et al Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J. Chemother. 21: Patel, R., K. E. Piper, M. S. Rouse, and J. M. Steckelberg Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob. Agents Chemother. 44: Rao, N., and C. W. Hamilton Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn. Microbiol. Infect. Dis. 59: Razonable, R. R., D. R. Osmon, and J. M. Steckelberg Linezolid therapy for orthopedic infections. Mayo Clin. Proc. 79: Rose, W. E., and P. T. Poppens Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63: Rouse, M. S., et al Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J. Antimicrob. Chemother. 57: Sacar, M., et al Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J. Surg. Res. 139: Saginur, R., et al Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50: Schaad, H. J., C. Chuard, P. Vaudaux, F. A. Waldvogel, and D. P. Lew Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38: Soriano, A., et al Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis. 26: Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279: Downloaded from on August 13, 2018 by guest
Efficacy of High Doses of Levofloxacin in Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2006, p. 4011 4017 Vol. 50, No. 12 0066-4804/06/$08.00 0 doi:10.1128/aac.00523-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Efficacy
More informationEfficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2009, p. 2719 2724 Vol. 53, No. 7 0066-4804/09/$08.00 0 doi:10.1128/aac.00047-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Efficacy
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationLinezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2009, p. 1142 1148 Vol. 53, No. 3 0066-4804/09/$08.00 0 doi:10.1128/aac.00775-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Linezolid
More informationReducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA
Reducing Infections in Surgical Practice Fred A Sweet, MD Rockford Spine Center Illinois, USA Introduction: How bacteria get in The Host The Surgeon The Procedure The STAFF Skin PREP Prophylactic Antibiotics
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationComparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1999, p. 667 671 Vol. 43, No. 3 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of Efficacies of Oral
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationAntibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More informationDual Antibiotic Delivery from Chitosan Sponges Prevents In Vivo Polymicrobial Biofilm Infections
Dual Antibiotic Delivery from Chitosan Sponges Prevents In Vivo Polymicrobial Biofilm Infections Ashley Parker, MS 1, James Smith, MS 1, Karen Beenken, PhD 2, Jessica Amber Jennings, PhD 3, Mark Smeltzer,
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationStaphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1994, p. 1703-1710 Vol. 38, No. 8 0066-4804/94/$04.00+0 Teicoplanin Alone or Combined with Rifampin Compared with Vancomycin for Prophylaxis and Treatment of
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationImpact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model
AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationMethicillin-Resistant Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1990, p. 2312-2317 0066-4804/90/122312-06$02.00/0 Copyright C 1990, American Society for Microbiology Vol. 34, No. 12 Treatment of Experimental Foreign Body
More informationComparison of Tigecycline and Vancomycin for. Treatment of Experimental Foreign Body Infection
AAC Accepts, published online ahead of print on 1 April 00 Antimicrob. Agents Chemother. doi:./aac.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationEradicating Carrier State of Methicillin-Resistant Staphylococcus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1990, p. 1655-1659 0066-4804/90/091655-05$02.00/0 Copyright 1990, American Society for Microbiology Vol. 34, No. 9 Efficacy of Short Courses of Oral Novobiocin-Rifampin
More informationOral antibiotic treatment of staphylococcal bone and joint infections in adults
J Antimicrob Chemother 2014; 69: 309 322 doi:10.1093/jac/dkt374 Advance Access publication 26 September 2013 Oral antibiotic treatment of staphylococcal bone and joint infections in adults Baek-Nam Kim
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationRole of Rifampin for Treatment of Orthopedic Implant Related Staphylococcal Infections
Role of Rifampin for Treatment of Orthopedic Implant Related Staphylococcal Infections A Randomized Controlled Trial Werner Zimmerli, MD; Andreas F. Widmer, MD, MSc; Marianne Blatter, MD; R. Frei, MD;
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationJAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationBurn Infection & Laboratory Diagnosis
Burn Infection & Laboratory Diagnosis Introduction Burns are one the most common forms of trauma. 2 million fires each years 1.2 million people with burn injuries 100000 hospitalization 5000 patients die
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationEffects of Minocycline and Other Antibiotics on Fusobacterium necrophorum Infections in Mice
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1975, p. 421-425 Copyright 0 1975 American Society for Microbiology Vol. 7, No. 4 Printed in U.S.A. Effects of Minocycline and Other s on Fusobacterium necrophorum
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationMicrobiology, University of Zürich, Switzerland
Journal of Antimicrobial Chemotherapy (2001) 47, 163 170 JAC In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationOne-Hit Wonders: A New Era of Antibiotics?
One-Hit Wonders: A New Era of Antibiotics? Patrick Wieruszewski, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds November 1, 2016 2016 MFMER slide-1 Objectives Identify advantages and disadvantages
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationGeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007
GeNei Bacterial Antibiotic Sensitivity Teaching Kit Manual Cat No. New Cat No. KT68 106333 Revision No.: 00180705 CONTENTS Page No. Objective 3 Principle 3 Kit Description 4 Materials Provided 5 Procedure
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationAbstract... i. Committee Membership... iii. Foreword... vii. 1 Scope Definitions... 1
Vol. 28 No. 7 Replaces M37-A2 Vol. 22 No. 7 Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline Third Edition
More informationQUESTION 11: What is the relevance of Minimum Inhibitory Concentration (MIC) of infecting organisms in biofilm-mediated chronic infection?
QUESTION 11: What is the relevance of Minimum Inhibitory Concentration (MIC) of infecting organisms in biofilm-mediated chronic infection? Authors: Jeppe Lange, Matthew Scarborough, Robert Townsend Response:
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationEnterococcal PJI. Miquel Ekkelenkamp
Enterococcal PJI Miquel Ekkelenkamp Enterococci: Gram-positive and round Formerly streptococci (but really quite different) Main clinical species : E. faecalis and E. faecium Mostly opportunistic pathogen
More informationConsiderations for antibiotic therapy. Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen
Considerations for antibiotic therapy Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen Infective Endocarditis There will never be a cure for this malignant disease! Sir
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationSaxena Sonal*, Singh Trishla* and Dutta Renu* (Received for publication January 2012)
J. Commun. Dis. 44(2) 2012 : 97-102 Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus at a tertiary care hospital: Implications for clinical therapy
More informationIn vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEmpirical Antibiotic Treatment of Disabled Veterans with Chronic Osteomyelitis
Iranian Journal of Military Medicine Vol. 14, No. 3, Autumn 2012; 229-234 Empirical Antibiotic Treatment of Disabled Veterans with Chronic Osteomyelitis Izadi M. 1, 2 MD, Musavi SA. 2, 4 MD, Foroutan SK.
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationTHE STABILITY OF E1VROFLOXA CIN University Undergraduate Research Fellow. A Senior Thesis. Texas ASM University.
THE STABILITY OF E1VROFLOXA CIN A Senior Thesis By Meagan A. Dodge 1997-98 University Undergraduate Research Fellow Texas ASM University Group: Biology THE STABILITY OF ENROFLOXACIN MEAGANA, DODGE Submitted
More informationVolume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article
Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article A STUDY ON ANTIBIOTIC SUSCEPTIBILITY
More informationNAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE. J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE and G. H.
46 THE JOURNAL OF ANTIBIOTICS APR. 1976 NAFCILLIN AND OXACILLIN COMPARATIVE ANTISTAPHYLOCOCCAL ACTIVITY IN MICE J. A. YURCHENCO, M. W. HOPPER, T. D. VINCE a G. H. WARREN Research Division, Wyeth Laboratories,
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationRESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN
RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant
More informationCONFLICT OF INTEREST ANTIMICROBIAL LOCK SOLUTIONS INCREASE BACTEREMIA
CONFLICT OF INTEREST ANTIMICROBIAL LOCK SOLUTIONS INCREASE BACTEREMIA NONE Vandana Dua Niyyar, MD Associate Professor of Medicine, Division of Nephrology, Emory University. OBJECTIVES Role of biofilm in
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationTOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY. Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya
16 THE JOURNAL OF ANTIBIOTICS JAN. 1972 TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya Biological Research Laboratories, Research
More information.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005
.'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationLocal Antibiotic Delivery with OsteoSet, DBX, and Collagraft
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH Number 451, pp. 29 33 2006 Lippincott Williams & Wilkins Local Antibiotic Delivery with OsteoSet, DBX, and Collagraft Andras Heijink, MD * ; Michael J. Yaszemski,
More information